Objective: To examine the odds associated with having medical comorbidities among patients with serious mental illness (SMI) in a large integrated health system.
Method: In a secondary analysis of electronic health record data, this study identified 25,090 patients with an ICD-9 SMI diagnosis of bipolar disorder (n=20,308) or schizophrenia (n=4782) and 25,090 controls who did not have a SMI, matched on age, gender, and medical home facility. Conditional logistic regressions compared the odds associated with having nine medical comorbidity categories and fifteen chronic or serious conditions among patients with SMI versus controls.
Results: Results showed having a SMI was associated with significantly higher odds of each medical comorbidity examined (p's<0.001), except no evidence of a significant association was found between having schizophrenia and musculoskeletal diseases. A similar pattern was found regarding the chronic or severe conditions, where having schizophrenia or bipolar was associated with >1.5 times the odds of each condition (p's<0.001).
Conclusions: In an integrated health system where patients may have fewer barriers to care, SMI patients are likely to present for treatment with a range of medical comorbidities, including chronic and severe conditions. SMI patients may need outreach strategies focused on disease prevention, screening and early diagnosis, and treatment to address medical comorbidities and associated poor health outcomes.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5576509 | PMC |
| http://dx.doi.org/10.1016/j.jpsychores.2017.07.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Shared decision-making (SDM) has the potential to significantly improve patient outcomes by enabling clinicians and patients to make health care decisions as partners. However, its implementation in mental health care has been a slow process. The objective of the study was to implement SDM during outpatient mental health treatment planning.
View Article and Find Full Text PDFRole of psychologists in enhancing care quality for individuals with serious mental illnesses: Introduction to a special section.
Psychol Serv
February 2025
Yale University School of Medicine, Department of Psychiatry.
This special section underscores the importance of psychologists in improving and enhancing care for individuals with serious mental illnesses (SMIs). People with diagnoses typically included in the category of SMIs-schizophrenia, schizoaffective disorder, bipolar disorder, and other diagnoses with symptoms severely impacting functioning-typically have layered marginalities and experience significant social stigma in addition to mental health symptoms. The complexity of challenges commonly experienced by individuals with SMI requires that treatment providers have specialized knowledge, training, and skills to provide specialty care needed to support mental health recovery.
View Article and Find Full Text PDF"I just felt that everything came tumbling down around me"-Barriers in cancer care for patients with severe mental illness: A qualitative study.
PLoS One
January 2025
Department of Oncology, Vejle Hospital, University Hospital of Southern Denmark, Odense, Denmark.
Background: Patients with severe mental illness experience serious inequity when facing cancer treatment. They are less likely to be referred for cancer treatment following recommended guidelines and have poorer cancer survival than patients without mental illness. Relevant specialties such as psychiatry and general practice are rarely involved, and the patient perspective is rarely represented in research in the field.
View Article and Find Full Text PDFIs the FAB test associated with fall occurrence in older adults? A retrospective analysis of outpatient fall risk assessment.
Eur Geriatr Med
January 2025
Department of Gerontology, Lille University Hospital, Lille, France.
Methods: We conducted a single-center, retrospective cohort study of French older adults. Participants with Mini-Mental State Examination (MMSE) ≥ 24 were recruited from a fall clinic in a geriatrics department. We recorded history of falls in the preceding 6 months, as well as Timed Up and Go test and mobility assessment at baseline and at 6- and 12-month follow-up.
View Article and Find Full Text PDFPharmacogenetic Testing for Predicting Methylphenidate Treatment Outcomes in Childhood Attention Deficit Hyperactivity Disorder in Turkey: Focus on Carboxylesterase 1, Latrophilin-3, and Catechol-O-Methyltransferase.
Am J Med Genet B Neuropsychiatr Genet
January 2025
Biruni University Research Center (B@MER), Biruni University, Istanbul, Turkey.
Pharmacogenetic studies involving Carboxylesterase 1 (CES1), Latrophilin-3 (LPHN3), and Catechol-O-methyltransferase (COMT) revealed individual differences regarding therapeutic response in children with attention deficit hyperactivity disorder (ADHD) under methylphenidate (MPH) treatment. This study aimed to evaluate MPH's association with the adverse effect status in children and its relationship with CES1, LPHN3, and COMT in the Turkish population. The study included 102 children and adolescents with ADHD, who were categorized as responders, or the adverse effect group based on their treatment response.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!